Health Care & Life Sciences » Pharmaceuticals | Bellerophon Therapeutics Inc.

Bellerophon Therapeutics Inc. | Ownership

Companies that own Bellerophon Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
New Mountain Vantage Advisers LLC
15,138,486
26.19%
0
0.97%
06/30/2018
Puissance Capital Management LP
8,298,755
14.36%
0
4.53%
06/30/2018
VHCP Management LLC
4,149,378
7.18%
0
0.93%
06/30/2018
Tavistock Life Sciences Co. (Investment Management)
1,857,143
3.21%
0
0.11%
06/30/2018
Renaissance Technologies LLC
1,159,200
2%
126,300
0%
06/30/2018
The Vanguard Group, Inc.
993,325
1.72%
15,905
0%
06/30/2018
Fidelity Management & Research Co.
647,671
1.12%
0
0%
06/30/2018
JPMorgan Securities LLC (Investment Management)
237,369
0.41%
215,004
0%
06/30/2018
EAM Investors LLC
232,290
0.4%
0
0.03%
06/30/2018
Geode Capital Management LLC
205,863
0.36%
61,312
0%
06/30/2018

About Bellerophon Therapeutics

View Profile
Address
184 Liberty Corner Road
Warren New Jersey 07059
United States
Employees -
Website http://www.bellerophon.com
Updated 07/08/2019
Bellerophon Therapeutics, Inc clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.